Abbott’s Cancer Diagnostics division, building on the legacy and innovations of Exact Sciences, is focused on advancing the early detection of colorectal cancer. The organization leverages proprietary, non-invasive molecular screening technologies originally developed at Exact Sciences, including stool-based DNA (sDNA) testing, which is recognized in screening guidelines from the American Cancer Society and the U.S. Multi-Society Task Force on Colorectal Cancer.

Abbott continues this mission by striving to detect cancer earlier and improve patient outcomes through a robust scientific platform and key collaborations, including work historically associated with Mayo Clinic. The organization is committed to expanding access to minimally invasive screening options, optimizing screening programs to improve patient compliance, and delivering high-quality data to support clinical decision-making.

By investing in its people, technology, and infrastructure, Abbott aims to create long-term, sustainable impact, delivering value to patients, healthcare providers, employees, investors, and the broader community.